By: Sophia Gilbukh, Paul Goldsmith-Pinkham & Michael Sinkinson (ProMarket)
When you go to a used car dealership, you know that the salespeople selling you a car want to make a big commission. Since you don’t buy a car very often, you might worry about being taken advantage of by a salesperson, either by overpaying or buying a car that is not a good match. A common solution would be to bring along someone who is an expert in cars to help you decide which one to buy. You might even pay them back (say, $100) for the time spent picking the best car for you and negotiating the price.
Economists think of the above as a solution to the problem of “asymmetric information”—the salesperson knows more than the potential buyer about the quality and market price of a given used car. By bringing along someone as an advisor, the gap in information between you and the salesperson decreases.
But what if the used car salesperson was the one who is paying your car advisor, and they were paying a fixed 2.5 percent commission of the selling price, conditional on sale? Moreover, the dealership set the commission rate and it was non-negotiable. Would this still seem like a good idea for a car buyer? Your advisor would now have an incentive to make sure you buy a car—any car, since they don’t get paid otherwise—and no incentive to negotiate a lower price…
Featured News
Top Antitrust Expert Joins Cravath from Paul Weiss
Jan 21, 2025 by
CPI
CMA Chief Removed as UK Government Targets Regulatory Overhaul
Jan 21, 2025 by
CPI
Court Denies Dismissal in Crab Price-Fixing Lawsuit
Jan 21, 2025 by
CPI
TikTok Stays Online for Now: Trump Floats US Ownership Deal
Jan 21, 2025 by
CPI
Hong Kong Watchdog Unveils Compliance Tool for Small Businesses
Jan 21, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Pharmacy Benefit Managers
Jan 20, 2025 by
CPI
Untangling the PBM Mess
Jan 20, 2025 by
Kent Bernard
Using Data, Not Anecdotes, to Analyze Criticisms of Pharmacy Benefit Managers
Jan 20, 2025 by
Dennis Carlton
Vertical Integration and PBMs: What, Me Worry?
Jan 20, 2025 by
Lawton Robert Burns & Bradley Fluegel
The Economics of Benefit Management in Prescription-Drug Markets
Jan 20, 2025 by
Casey B. Mulligan